Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Required:

- PCP prophylaxis consisting of Bactrim, aerosolized pentamidine, or dapsone.

Recommended:

- Antiemetic therapy within 30 minutes of chemotherapy.

Allowed:

- Antiretroviral medication after two cycles of chemotherapy, provided the patient has
not experienced grade 3 neutropenia while on chemotherapy or on previous
antiretroviral therapy.

- Acetaminophen and/or nonsteroidal anti-inflammatory agents.

- Bone marrow-suppressive agents, such as ganciclovir, Fansidar, Bactrim, and dapsone.

- Maintenance therapy for chronic opportunistic infection.

Concurrent Treatment:

Allowed:

- Cranial irradiation (2400 rads) for patients with CNS involvement.

Patients must have:

- Documented HIV infection or diagnosis of AIDS.

- Hodgkin's disease.

- Consent of parent or guardian and have care directly supervised by a pediatric
oncologist if under 18 years of age.

Prior Medication:

Allowed:

- Maintenance therapy for opportunistic infections.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Second primary cancer other than Kaposi's sarcoma that does not require systemic
therapy, nonmelanomatous skin cancer, Bowen's disease, or carcinoma in situ of the
cervix.

- Acute, active bacterial or opportunistic infection requiring ongoing therapy if such
therapy has been initiated within the past 2 weeks.

- Known hypersensitivity (e.g., anaphylactoid reaction, bronchospasm) to E.
coli-derived proteins.

Prior Medication:

Excluded:

- Prior chemotherapy for Hodgkin's disease.

- Antiretroviral therapy within 2 weeks prior to study entry.

Prior Treatment:

Excluded:

- Prior radiotherapy for Hodgkin's disease.